StockData
Genenta Science S.p.A. logo

Genenta Science S.p.A. (SAEN) stock

SAENNasdaqBiological Products, (No Diagnostic Substances)Also trades as GNTA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.60−0.05 (-7.66%)

Close on Nov 16, 2026Market cap $14.06MP/E –Yield –

Genenta Science S.p.A. r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €2.70M, down 43.9% from the year before. The highest annual figure on record is €6.47M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€2.70M-43.9%
FY2024Dec 31, 2024€4.81M-25.7%
FY2023Dec 31, 2023€6.47M+21.3%
FY2022Dec 31, 2022€5.34M+57.5%
FY2021Dec 31, 2021€3.39M-27.7%
FY2020Dec 31, 2020€4.69M+26.6%
FY2019Dec 31, 2019€3.70M–

More Genenta Science S.p.A. figures

See a number that looks wrong?